1122089-67-1

Usage

Uses

Used in Pharmacological Research:
2-cyclopentyl-6-methoxypyridine-4-carboxylic acid is used as a research compound for exploring its potential therapeutic properties, such as anti-inflammatory, analgesic, and neuroprotective effects.
Used in Drug Development:
2-cyclopentyl-6-methoxypyridine-4-carboxylic acid is utilized as a candidate for developing new drugs targeting various medical conditions, including neurological disorders and inflammatory conditions, due to its demonstrated potential in these areas.
Used in Treatment of Neurological Disorders:
In the field of neurology, 2-cyclopentyl-6-methoxypyridine-4-carboxylic acid is used as a potential therapeutic agent for the treatment of neurological disorders, leveraging its neuroprotective properties to safeguard neurons from damage and degeneration.
Used in Treatment of Inflammatory Conditions:
In the realm of inflammation management, 2-cyclopentyl-6-methoxypyridine-4-carboxylic acid is employed as a potential treatment option for inflammatory conditions, capitalizing on its anti-inflammatory properties to reduce inflammation and alleviate symptoms.

Upstream product

• 67-56-1 methanol 
• 1033443-97-8 ethyl 4-cyclopentyl-2,4-dioxobutanoate 
• 28247-15-6 ethyl 1-acetylcyclopropane-1-carboxylate 
• 6004-60-0 1-cyclopentylethanone 
• 138837-21-5 tert-butyl 1-acetylcyclopentanecarboxylate 
• 865-33-8 potassium methanolate 
• 1368348-22-4 2-cyclopentyl-6-hydroxyisonicotinic acid 
• 42521-09-5 methyl 2,6-dichloroisonicotinate 
• 1262413-92-2 2-cyclopentyl-6-methoxyisonicotinic acid methyl ester 
• 42521-10-8 2-chloro-6-methoxyisonicotinic acid methyl ester 
• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 15855-06-8 2-chloro-6-methoxy-isonicotinic acid 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 1391464-10-0 3-(2-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}ethylamino)propionic acid 
• 1391465-35-2 2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethanol 
• 1391465-37-4 2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethyl methanesulfonate 
• 1391465-38-5 ethyl 3-((2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethyl)amino)propanoate 
• 1391465-39-6 (S)-5-(2-cyclopentyl-6-methoxypyridin-4-yl)-3-(3-ethyl-5-methyl-4-(oxiran-2-ylmethoxy)phenyl)-1,2,4-oxadiazole 
• 1391464-17-7 {4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}acetic acid 
• 1391465-41-0 (S)-2-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)amino)acetic acid ethyl ester 
• 1391464-24-6 ((S)-3-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}-2-hydroxypropylamino)acetic acid 
• 1391464-32-6 2-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}-N-(2-hydroxyethyl)acetamide 
• 1391465-43-2 (S)-1-amino-3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)propan-2-ol 
• 1391465-46-5 (S)-ethyl 3-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)amino)-3-oxopropanoate 
• 1391464-33-7 (S)-3-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)amino)-3-oxopropanoic acid 
• 1391464-52-0 2-(2-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}ethylamino)ethanol 
• 1391465-47-6 rac-2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-N-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)ethanamine 

Relevant academic research and scientific papers

S1P1 AGONIST AND APPLICATION THEREOF

The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.

Preparation method of novel anti-ultraviolet plastic additive

The invention discloses a preparation method of a novel anti-ultraviolet plastic additive and belongs to the technical field of plastic additive synthesis. The novel anti-ultraviolet plastic additive has a structure described in the specification, wherein R1 is an oxygen atom or nitrogen atom; and R2 is cyclopentane, cyclobutane or cyclopropane; and R3 is methyl, ethyl or phenyl. The invention also discloses a preparation method of the novel anti-ultraviolet plastic additive. According to the invention, a new anti-ultraviolet plastic additive is synthesized by virtue of a new method, reaction process operation is simple and practicable, raw materials are cheap and available, reaction efficiency is relatively high and repeatability is relatively good, and the novel anti-ultraviolet plastic additive has a good anti-ultraviolet radiation ageing effect on plastic.

Synthetic method of novel feed additive

The invention discloses a synthetic method of a novel feed additive and belongs to the technical field of synthesis of feed additives. The novel feed additive has the structure shown in the specification, wherein R1 is an oxygen atom or a nitrogen atom, R2 is cyclopentane, cyclobutane or cyclopropane, and R3 is methyl, ethyl or phenyl. The invention further discloses a preparation method of the novel feed additive. The novel feed additive is synthesized with the novel method, operation is simple and easy to perform in the reaction process, raw materials are low in price and easy to obtain, the reaction efficiency is relatively high, the repetition is relatively good, and the novel feed additive has a good growth promoting function on grow-finishing pigs.

Practical Synthesis of a S1P Receptor 1 Agonist via a Guareschi-Thorpe Reaction

A practical synthesis of S1P receptor 1 agonist ACT-334441 (1) through late-stage convergent coupling of two key intermediates is described. The first intermediate is 2-cyclopentyl-6-methoxyisonicotinic acid whose skeleton was built from 1-cyclopentylethanone, ethyl oxalate, and cyanoacetate in a Guareschi-Thorpe reaction in 42% yield over five steps. The second, chiral intermediate, is a phenol ether derived from enantiomerically pure (R)-isopropylidene glycerol ((R)-solketal) and 3-ethyl-4-hydroxy-5-methylbenzonitrile in 71% yield in a one-pot reaction. The overall sequence entails 18 chemical steps with 10 isolated intermediates. All raw materials are cheap and readily available in bulk quantities, the reaction conditions match with standard pilot plant equipment, and the route reproducibly afforded 3-20 kg of 1 in excellent purity and yield for clinical studies.

Novel S1P1 receptor agonists - Part 5: From amino-to alkoxy-pyridines

In a previous communication we reported on the discovery of aminopyridine 1 as a potent, selective and orally active S1P1 receptor agonist. More detailed studies revealed that this compound is phototoxic in vitro. As a result of efforts aiming at eliminating this undesired property, a series of alkoxy substituted pyridine derivatives was discovered. The photo irritancy factor (PIF) of these alkoxy pyridines was significantly lower than the one of aminopyridine 1 and most compounds were not phototoxic. Focused SAR studies showed, that 2-, 3-, and 4-pyridine derivatives delivered highly potent S1P1 receptor agonists. While the 2-pyridines were clearly more selective against S1PR3, the corresponding 3- or 4-pyridine analogues showed significantly longer oral half-lives and as a consequence longer pharmacological duration of action after oral administration. One of the best compounds, cyclopentoxy-pyridine 45b lacked phototoxicity, showed EC50 values of 0.7 and 140 nM on S1PR1 and S1PR3, respectively, and maximally reduced the blood lymphocyte count for at least 24 h after oral administration of 10 mg/kg to Wistar rats.

NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID

The present invention relates to new processes for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid, which is a useful intermediate for the synthesis of pyridine-4-yl derivatives as immunomodulating agent. Moreover, the present invention also relates to new intermediates used in those processes.

2-METHOXY-PYRIDIN-4-YL-DERIVATIVES

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

2-METHOXY-PYRIDIN-4-YL DERIVATIVES

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDIN-4-YL DERIVATIVES

The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDIN-4-YL DERIVATIVES

The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.